A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Juliana Hutchinson, MSc
- Telefoonnummer: +4161 551 75 75
- E-mail: clinical.trial.enquiry@windwardbio.com
Studie Locaties
-
-
Buenos Aires
-
Buenos Aires, Buenos Aires, Argentinië, C1023AAB
- Werving
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentinië, C1028AAP
- Werving
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentinië, C1122AAK
- Werving
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentinië, C1425BEN
- Werving
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentinië, C1425FVH
- Werving
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentinië, C142ABP
- Werving
- WB Contracted Clinical Research Site
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentinië, C1414AIF
- Werving
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires F.D., Argentinië, C1426ABP
- Werving
- WB Contracted Clinical Research Site
-
-
Mendoza Province
-
Buenos Aires, Mendoza Province, Argentinië, M5500AXR
- Werving
- WB Contracted Clinical Research Site
-
Mendoza, Mendoza Province, Argentinië, M5500CBA
- Werving
- WB Contracted Clinical Research Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentinië, S2000KZD
- Werving
- WB Contracted Clinical Research Site
-
Rosario, Santa Fe Province, Argentinië, S2013OJN
- Werving
- WB Contracted Clinical Research Site
-
Santa Fe, Santa Fe Province, Argentinië, S3000ASF
- Werving
- WB Contracted Clinical Research Site
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 93534
- Werving
- WB Contracted Clinical Research Site
-
-
Florida
-
Miami Lakes, Florida, Verenigde Staten, 33014
- Werving
- WB Contracted Clinical Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Verenigde Staten, 02747
- Werving
- WB Contracted Clinical Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28277
- Werving
- WB Contracted Clinical Research Site
-
-
Oregon
-
Medford, Oregon, Verenigde Staten, 97504
- Werving
- WB Contracted Clinical Research Site
-
-
Pennsylvania
-
DuBois, Pennsylvania, Verenigde Staten, 15801
- Werving
- WB Contracted Clinical Research Site
-
-
Texas
-
McKinney, Texas, Verenigde Staten, 75069
- Werving
- WB Contracted Clinical Research Site
-
Waxahachie, Texas, Verenigde Staten, 75165
- Werving
- WB Contracted Clinical Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Adults aged 40 to 80 years
- Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
- On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
- Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
- Elevated eosinophil count
- Weight/BMI within allowed range
Exclusion Criteria:
- Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
- Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
- Clinically significant cardiovascular disease
- Recent respiratory infection or COPD exacerbation
- Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
- Pregnancy or breastfeeding
- Smoking or diagnosed substance use disorder
- Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: WIN378 Dose 1
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Experimenteel: WIN378 Dose 2
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Experimenteel: Placebo
Placebo SC injections will be administered
|
Placebo matching WIN378
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Number of participants with Serious Adverse Events (SAEs)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in systolic blood pressure (mmHg)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in diastolic blood pressure (mmHg)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in pulse rate (beats/minute)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in respiratory rate (breaths/minute)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in oxygen saturation (%)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body weight (kg)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body mass index (kg/m^2)
Tijdsspanne: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body temperature (°C)
Tijdsspanne: Week 0- Week 36
|
Week 0- Week 36
|
|
|
Change from baseline in clinical chemistry laboratory assessments
Tijdsspanne: Week 0 - Week 36
|
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
|
Week 0 - Week 36
|
|
Change from baseline in haematology laboratory parameters
Tijdsspanne: Week 0 - Week 36
|
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
|
Week 0 - Week 36
|
|
Change from baseline in coagulation laboratory parameters
Tijdsspanne: Week 0 - Week 36
|
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
|
Week 0 - Week 36
|
|
Change from baseline in urinalysis parameters
Tijdsspanne: Week 0 - Week 36
|
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
|
Week 0 - Week 36
|
|
Change from baseline in electrocardiogram QT interval
Tijdsspanne: Week 0 - Week 36
|
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
|
Week 0 - Week 36
|
|
WIN378 Serum concentration (PK)
Tijdsspanne: Week 0 to week 36
|
Week 0 to week 36
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change from baseline in Blood Eosinophil Count
Tijdsspanne: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Fractional Exhaled Nitric Oxide (FeNO)
Tijdsspanne: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tijdsspanne: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Tijdsspanne: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Incidence and magnitude of anti-drug antibodies to WIN 378
Tijdsspanne: Week 0 to Week 36
|
Week 0 to Week 36
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Studie directeur: Omar Khwaja, MD, Windward Bio
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- WB-2102
- U1111-1333-4974 (Andere identificatie: UTN, World Health Organization (WHO))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .